Identity
Octinoxate — INCI name ethylhexyl methoxycinnamate, also known as octyl methoxycinnamate (OMC) or EHMC — is a cinnamate ester UVB filter. It has been the most widely used UVB filter in cosmetics for decades, appearing not only in sunscreens but in hair colour, shampoos, lipsticks, nail polish and creams, where it also serves to protect the product from UV degradation.
⚠️ The "oct-" cluster is a common source of error. Octinoxate (a cinnamate), octocrylene (also a cinnamate derivative, different molecule), and octisalate (ethylhexyl salicylate, a salicylate) are three separate filters with similar names.
What it does, and what it does not
Octinoxate absorbs UVB across roughly 290-320 nm, peaking at 311 nm. It is cosmetically excellent — spreadable, non-greasy — which is a large part of why it dominated formulation for so long.
It provides no UVA protection. Not long UVA, not short UVA. This is the single most important practical fact about it: a product relying on octinoxate for its SPF is protecting against sunburn while leaving the wavelengths responsible for photoageing and pigmentation entirely to whatever else is in the formula.
It is also photounstable, degrading via photoisomerization — UV exposure alters its molecular structure and reduces its absorption capacity. Unlike avobenzone's tautomerism, which has well-established stabilisation routes, octinoxate's instability is usually managed by reapplication or by pairing with photostable filters such as bemotrizinol, which is documented as keeping both avobenzone and octinoxate active through sustained exposure.
One further formulation trap: avobenzone-octinoxate combinations have shown phototoxic potential in testing. Pairing them to cover the UVA gap is not automatically safe without proper stabilisation.
Reading the evidence honestly
The endocrine file is substantial, and it is not settled. Estrogenic, anti-progestogenic and anti-thyroid activity have been reported across species; a dedicated study combined in vivo and in vitro data on thyroid hormone disruption; epidemiological, ex vivo and in vitro human work has reported cardiovascular, thyroid, reproductive and immunological effects; and it is detected in human urine, blood and breast milk. The review literature states directly that no consensus exists in the scientific community about its use. That is the honest position — not exoneration, and not proof of harm.
The correction worth making. Octinoxate and oxybenzone are treated as a matched pair by regulation and by public discussion — banned together, discussed together, avoided together. On systemic absorption they are not equivalent: octinoxate shows lower dermal penetration and lower systemic absorption than benzophenone-3, and at least one review describes it as the safer of the two on that basis. Its concerns are weighted toward endocrine activity and photoinstability; oxybenzone's toward sheer exposure. Lumping them obscures a real difference.
Where it quietly outperforms. Octinoxate has notably low sensitisation potential — it rarely causes contact or photocontact allergy, unlike octocrylene, oxybenzone and avobenzone. For someone whose problem with sunscreen is reactions rather than theoretical endocrine concerns, that is not a trivial point.
On the environment. Octinoxate is banned alongside oxybenzone in Hawaii, Key West, the US Virgin Islands, Palau, Aruba, Bonaire and elsewhere. The coral-toxicity evidence carries the same methodological criticism documented on the oxybenzone entry, and the same attribution caveat applies: climate change is the dominant driver of coral decline. There is also a distinct finding worth knowing — UV filters including octinoxate have been reported to increase viral abundance in marine bacterioplankton through prophage induction, an ecosystem-level effect separate from direct coral toxicity.
A scale note that rarely gets made. Because octinoxate appears in around 90% of personal care products historically, a full ban would remove an enormous share of the cosmetic market — a practical consideration that the literature raises explicitly, and one that has shaped regulatory caution as much as the science has.
And the market moved first. Reported usage fell around 70% between 2020 and 2025, driven by consumer demand rather than by any regulatory determination — the FDA still has not reached a GRASE conclusion, and the EU review continues. As with oxybenzone, the practical argument has become less about litigating the controversy and more about the availability of better filters: bemotrizinol, DHHB and ethylhexyl triazone all outperform it on spectrum, photostability, or both.